Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Balinatunfib
SAR441566 · 6 trials · 4 indications
ACR20 response criteria is a dichotomous composite endpoint indicating the proportion of participants with at least 20 percent improvement in the number of tender and swollen joints, and in three out of the remaining five ACR core-set measures: patient pain (VAS, No pain to Severe Pain), Patient Global Assessment of disease activity (VAS, Very well to Very Poor), physician global assessment of disease activity (VAS, Very good to Very bad), physical functioning assessment (Health Assessment Questionnaire-Disability Index \[HAQ-DI\]), and acute phase reactants (ESR or CRP mg/dl; in this study CRP will be used). ACR response is scored as a percentage improvement, comparing disease activity at two discrete time points. ACR20 is ≥ 20% improvement.
PASI is linear combination of percent of surface area of skin that is affected and severity of erythema(E),induration(i),desquamation(D) over 4 body regions: head(h),trunk(t),upper extremities(u),lower extremities(l). The signs of severity, E, i and D of lesions are assessed using numeric scale for which scores are made independently for each of the areas; range:0 (complete lack of cutaneous involvement) to 4 (severest possible involvement). For each body area, percentage of considered body area covered by plaque psoriasis is translated into numerical value "Ax":0=no involvement,1=\<10% to 6=90 to 100% involvement. These scores are noted Ah, At, Au, and Al in formula below. The PASI score is calculated according to the following formula: PASI = 0.1(Eh+ih+Dh)Ah + 0.3(Et+it+Dt)At + 0.2(Eu+iu+Du)Au + 0.4(El+il+Dl)Al. PASI score range:0 (no disease) to 72 (maximal disease);higher scores: greater psoriasis severity. Percentage of participants with PASI75 at Week 12 is presented.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 1 is Full range solar ultraviolet B/ultraviolet A (UVB/UVA) \[290 to 400 nm\] exposure.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 1 is a Full range solar UVB/UVA \[290 to 400 nm\] exposure.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.
The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.
Maximum plasma concentration observed
Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time Tlast (AUClast)
Area under the plasma concentration versus time curve extrapolated to infinity (AUC)
Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE) including SAE and AESI
| Arm | Type | Description |
|---|---|---|
| SAR441566 dose regimen A | EXPERIMENTAL | Participant will receive dose regimen A of SAR441566 for 12 weeks |
| SAR441566 dose regimen B | EXPERIMENTAL | Participant will receive dose regimen B of SAR441566 for 12 weeks |
| SAR441566 dose regimen C | EXPERIMENTAL | Participant will receive dose regimen C of SAR441566 for 12 weeks |
| SAR441566 dose regimen D | EXPERIMENTAL | Participant will receive dose regimen D of SAR441566 for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Participant will receive SAR441566-matching placebo for 12 weeks |
| SAR441566 dose regimen E | EXPERIMENTAL | Participants received dose regimen E of SAR441566 |
| Balinatunfib Treatment A | EXPERIMENTAL | Participants will receive a single oral dose of balinatunfib. |
| Balinatunfib Treatment B | EXPERIMENTAL | Participants will receive a single oral dose of balinatunfib. |
| Moxifloxacin Treatment C | ACTIVE_COMPARATOR | Participants will receive a single oral dose of moxifloxacin. |
| Placebo Treatment D | PLACEBO_COMPARATOR | Participants will receive a single oral dose of balinatunfib matching placebo and moxifloxacin matching placebo. |
| Part I SAR441566 Dose A | EXPERIMENTAL | Participants will receive repeated low dose of SAR441566 for 7.5 days |
| Part I SAR441566 Dose B | EXPERIMENTAL | Participants will receive repeated high dose of SAR441566 for 7.5 days |
| Part I Placebo | PLACEBO_COMPARATOR | Participants will receive repeated SAR441566 matching placebo tablets for 7.5 days |
| Part II Ciprofloxacin | ACTIVE_COMPARATOR | Participants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days |
| SAR441566 | EXPERIMENTAL | Participants will receive single ascending doses of SAR441566 on day 1 of each 8-12-day cycle |
| Name | Type | Description |
|---|---|---|
| SAR441566 | DRUG | Tablet |
| Placebo | DRUG | Tablet |
| Balinatunfib | DRUG | Pharmaceutical form: Tablet Route of administration: Oral |
| Moxifloxacin | DRUG | Pharmaceutical form: Tablet Route of administration: Oral |
| Ciprofloxacin | DRUG | Tablet |
Inclusion Criteria: * Diagnosis of adult-onset RA classified by ACR/EULAR 2010 revised classification criteria for RA of at least 3 months duration, with the onset of signs and symptoms of RA of at least 6 months duration * Moderate-to-severely active RA, defined as: * persistently active diseas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 5 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
| Amgen Inc. | AMGN | 1 | PHASE1 | Apremilast, Apremilast IR |
SAR441566 is an investigational small molecule developed by Sanofi for the treatment of psoriasis and rheumatoid arthritis. It has been studied in adults with plaque psoriasis and in adults with rheumatoid arthritis, with Phase 2 trials completed in both indications. It is not described as approved for any use.
SAR441566 is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of the compound and sponsored the clinical trials evaluating it in plaque psoriasis, rheumatoid arthritis, and healthy volunteers.
SAR441566 is in Phase 2. Two Phase 2 trials have been completed: one in adults with plaque psoriasis and one in adults with rheumatoid arthritis. Earlier Phase 1 studies in healthy volunteers, including a Japanese male single ascending dose study and a photosafety study, are also completed.
SAR441566 has been evaluated in completed trials including NCT06073119, a Phase 2 study in plaque psoriasis enrolling 221 adults across 17 countries, and NCT06073093, a Phase 2 study in rheumatoid arthritis enrolling 264 adults. Phase 1 studies include NCT05858788 and NCT05844735 in healthy volunteers.
Across the listed studies, 334 participants were enrolled in SAR441566 trials. The largest was the Phase 2 rheumatoid arthritis study with 264 participants, followed by the Phase 2 plaque psoriasis study with 221 participants. The Phase 1 photosafety and Japanese single ascending dose studies enrolled 60 and 10 healthy volunteers respectively.
Yes. The SAR441566 clinical program includes randomized, double-blind, placebo-controlled trials. The Phase 2 studies in plaque psoriasis and rheumatoid arthritis used placebo controls, and a Phase 1 study, NCT05844735, was randomized with both placebo and active comparator arms to evaluate photosafety.